Cite
MLA Citation
A.J. Arribas et al.. “DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL).” Hematological oncology, vol. 35, n.d., p. 254. http://access.bl.uk/ark:/81055/vdc_100047426577.0x00002f